Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback